arrow
N

Nicholas Marston

brigham and women s hospital
H指数:27
被引数:4,052

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Apolipoprotein B-containing lipoproteins: distinct roles in atherosclerosis revealed by plasma proteomic profiling

载脂蛋白B-含脂蛋白:血浆蛋白质组学分析揭示其在动脉粥样硬化中的不同作用

2026-08-310
OAAI
Prioritizing Discovery and Advancements in Arrhythmia Therapies NIH/NHLBI Workshop

优先考虑心律失常治疗领域的发现与进展:NIH/NHLBI研讨会

2026-06-010
PRE
Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction

主动脉狭窄的基因组和转录组学分析可增强治疗靶点的发现和疾病预测

2025-12-190
OAAI
Letter to the Editor: No Time to Waste-Upfront Combination Lipid Lowering Therapy for Post-Acute Coronary Syndromes, Regarding the: National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Comprehensive Australian Clinical Guideline for Diagnosing and Managing Acute Coronary Syndromes 2025 by Brieger et al., Heart Lung Circ. 2025;34:309-397.

致编辑信:没有时间浪费——急性冠脉综合征后的一线联合降脂疗法,关于:澳大利亚国家心脏基金会与澳大利亚和新西兰心脏学会:急性冠脉综合征诊断和管理综合澳大利亚临床指南2025(Brieger等人,Heart Lung Circ. 2025;34:309-397)。

2025-12-010
PRE
A polygenic risk score for peripheral artery disease and major adverse limb events

外周动脉疾病及主要肢体不良事件的polygenic risk score

2025-11-010
PRE
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk

奥利泽森(Olezarsen)用于管理严重高甘油三酯血症及胰腺炎风险

2025-11-015
PRE
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke

Evolocumab在无既往心肌梗死或卒中史患者中的应用

2025-11-0111
PRE
Polygenic risk score for coronary artery disease across the spectrum of atherosclerotic disease

动脉粥样硬化疾病谱中冠状动脉疾病的多基因风险评分

2025-11-010
PRE
Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation

致病性心肌病相关基因变异与心房颤动的预后

JACC
IF0
2025-09-010
PRE
A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk

一种用于预测全谱心血管风险范围内新发心力衰竭的多基因风险评分

JACC
IF0
2025-08-270
PRE
Polygenic Risk in Heart Failure - Evaluating the Ability of a Polygenic Risk Score to Identify Risk of Future Heart Failure Events in 60,000 Patients from 6 TIMI Randomized Trials

多基因风险与心力衰竭——评估多基因风险评分在识别6项TIMI随机试验中60,000名患者未来心力衰竭事件风险方面的能力

2024-11-120
PRE